Insurers View JUPITER With Caution; Can Benefit Be Achieved With Generics?

As insurers begin to review the details of AstraZeneca's headline-making outcomes study on Crestor - the JUPITER trial - a key question is whether the benefit found can also be extrapolated to less expensive statins, including generics